Page 28 - IJB-6-4

Bioprinting, microfluidics, and organoids to defeat COVID-19
8(330): 330ra36. DOI: 10.1126/scitranslmed.aaf1517. 28. Radigan KA, Misharin AV, Chi M, et al., 2015, Modeling
17. Henle W, Henle G, Stokes J Jr., 1943, Demonstration of the Human Influenza Infection in the Laboratory. Infect Drug
Efficacy of Vaccination Against Influenza Type A by Experimental Resist, 8:311–20. DOI: 10.2147/idr.s58551.
Infection of Human Beings. J Immunol, 46(3):163–75. 29. Dowall SD, Graham VA, Rayner E, et al. 2016, A Susceptible
18. Jackson GG, Muldon RL, Akers LW, 1963, Serological Mouse Model for Zika Virus Infection. PLoS Negl Trop Dis,
Evidence for Prevention of Influenzal Infection in Volunteers 10(5):e0004658.
by an Anti-influenzal Drug Adamantanamine Hydrochloride. 30. Ter Meulen J, Bakker AB, Van Den Brink EN, et al., 2004,
Antimicrob Agents Chemother, 161:703–7. Human Monoclonal Antibody as Prophylaxis for SARS
19. Calfee DP, Peng AW, Cass LM, et al., 1999, Safety and Efficacy Coronavirus Infection in Ferrets. Lancet, 363(9427):2139–
of Intravenous Zanamivir in Preventing Experimental Human 41. DOI: 10.1016/s0140-6736(04)16506-9.
Influenza A Virus Infection. Antimicrob Agents Chemother, 31. Ng PS, Böhm R, Hartley-Tassell LE, et al., 2014, Ferrets
43(7):1616–20. DOI: 10.1128/aac.43.7.1616. Exclusively Synthesize Neu5Ac and Express Naturally
20. Hayden FG, Zylidnikov DM, Iljenko VI, et al., 1982, Humanized Influenza A Virus Receptors. Nat Commun,
Comparative Therapeutic Effect of Aerosolized and Oral 5(1):1–9. DOI: 10.1038/ncomms6750.
Rimantadine HC1 in Experimental Human Influenza A Virus 32. Hancock GE, Smith JD, Heers KM, 2000, Serum Neutralizing
Infection. Antiviral Res, 2(3):147–53. DOI: 10.1016/0166- Antibody Titers of Seropositive Chimpanzees Immunized
3542(82)90016-x. with Vaccines Coformulated with Natural Fusion and
21. Hayden FG, Treanor JJ, Fritz RS, et al., 1999, Use of the Oral Attachment Proteins of Respiratory Syncytial Virus. J Infect
Neuraminidase Inhibitor Oseltamivir in Experimental Human Dis, 181(5):1768–71. DOI: 10.1086/315475.
Influenza Randomized Controlled Trials for Prevention 33. Clarke CJ, Watt NJ, Meredith A, et al., 1994, Respiratory
and Treatment. JAMA, 282(13):1240-6. DOI: 10.1001/ Syncytial Virus-associated Bronchopneumonia in a Young
jama.282.13.1240. Chimpanzee. J Comp Pathol, 110(2):207–12. DOI: 10.1016/
22. Mironov V, Visconti R, Kasyanov V, et al., 2009, Organ s0021-9975(08)80191-0.
Printing: Tissue Spheroids as Building Blocks. Biomaterials, 34. Perrin S, 2014, Make Mouse Studies Work. Nature, 517:423–5.
30(12):2164–74. DOI: 10.1016/j.biomaterials.2008.12.084. 35. Ito R, Takahashi T, Ito M, 2018, Humanized Mouse Models:
23. Gubareva LV, Kaiser L, Matrosovich MN, et al., 2001, Application to Human Diseases. J Cell Physiol, 233:3723–8.
Selection of Influenza Virus Mutants in Experimentally DOI: 10.1002/jcp.26045.
Infected Volunteers Treated with Oseltamivir. J Infect Dis, 36. Walsh NC, Kenney LL, Jangalwe S, et al., 2017,
183(4):523–31. DOI: 10.1086/318537. Humanized Mouse Models of Clinical Disease. Annu Rev
24. McCallin S, Sarker SA, Sultana S, et al., 2018, Metagenome Pathol Mech Dis, 12(1):187–215. DOI: 10.1146/annurev-
Analysis of Russian and Georgian Pyophage Cocktails and a pathol-052016-100332.
Placebo-Controlled Safety Trial of Single Phage Versus Phage 37. Kistner O, Barrett PN, Mundt W, et al., 1998, Development
Cocktail in Healthy Staphylococcus aureus Carriers. Environ of a Mammalian Cell (Vero) Derived Candidate Influenza
Microbiol, 20(9):3278–93. DOI: 10.1111/1462-2920.14310. Virus Vaccine. Vaccine, 16(9-10):960–8. DOI: 10.1016/
25. Jault P, Leclerc T, Jennes S, et al., 2019, Efficacy and s0264-410x(97)00301-0.
Tolerability of a Cocktail of Bacteriophages to Treat Burn 38. de Lang A, Osterhaus AD, Haagmans BL, 2006, Interferon-γ
Wounds Infected by Pseudomonas aeruginosa (PhagoBurn): and Interleukin-4 Downregulate Expression of the SARS
A Randomised, Controlled, Double-Blind Phase 1/2 Trial. Coronavirus Receptor ACE2 in Vero E6 Cells. Virology,
Lancet Infect Dis, 19(1):35–45. DOI: 10.1016/s1473- 353(2):474–81. DOI: 10.1016/j.virol.2006.06.011.
3099(18)30482-1. 39. Bhowmick R, Derakhshan T, Liang Y, et al., 2018, A Three-
26. Febvre HP, Rao S, Gindin M, et al., 2019, PHAGE Dimensional Human Tissue-Engineered Lung Model to Study
Study: Effects of Supplemental Bacteriophage Intake Influenza A Infection. Tissue Eng Part A, 24(19-20):1468–80.
on Inflammation and Gut Microbiota in Healthy Adults. DOI: 10.1089/ten.tea.2017.0449.
Nutrients, 11(3):666. DOI: 10.3390/nu11030666. 40. Dill V, Hoffmann B, Zimmer A, et al., 2018, Influence of Cell
27. Bem RA, Domachowske JB, Rosenberg HF, 2011, Animal Type and Cell Culture Media on the Propagation of Foot-and-
Models of Human Respiratory Syncytial Virus Disease. Am J Mouth Disease Virus with Regard to Vaccine Quality. Virol J,
Physiol Lung Cell Mol Physiol, 301:L148-56. 15(1):1–11. DOI: 10.1186/s12985-018-0956-0.

24 International Journal of Bioprinting (2020)–Volume 6, Issue 4